Search

Event-free survival considers other adverse events in addition to mortality. It therefore provides a more complete understanding of the effectiveness and consequences of treatment than standard survival measures, but is rarely reported at the population level for childhood cancer.

Children receiving treatment for acute myeloid leukemia (AML) are at high risk of invasive fungal disease (IFD). Evidence from pediatric studies support the efficacy of antifungal prophylaxis in reducing the burden of IFD in children receiving therapy for AML, yet existing antifungal agents have specific limitations and comparative data to inform the optimal prophylactic approach are lacking.

Viridans group streptococci (VGS) are an important cause of sepsis in immunosuppressed children. We reviewed the effectiveness of risk-stratified addition of vancomycin to empiric febrile neutropenia therapy among 107 children with leukemia or undergoing an allogeneic transplant.

To investigate incidence and survival of childhood tumours of the central nervous system (CNS) by histological subtype, tumour behaviour and tumour grade. Methods: National, population-based data on all children under 15 years old diagnosed with a CNS tumour between 1983 and 2016 were sourced from the Australian Childhood Cancer Registry. Incidence rate trends were calculated using Joinpoint regression.

The Robert Connor Dawes Foundation has joined forces with the Ethan Davies Fellowship to co-fund a The Kids Research Institute Australia initiative aimed at uncovering new treatments for aggressive childhood brain tumours.

This year for Childhood Cancer Awareness Month, we got to know the sarcoma research team at Telethon Kids.

The Cancer Immunology team at The Kids is investigating how the body's 'natural killer' cells can be harnessed to fight cancer – whilst also protecting kids from nasty chemotherapy side effects.

The Kids Research Institute Australia researchers may have unlocked a vital key to reducing the progression of leukaemia in children, potentially prompting a change in thinking around the best way to target treatment.

Dr Nick Gottardo, Co-Head of The Kids Research Institute Australia's Brain Tumour Research Team, has been announced a nominee for the 2018 WA Australian of the Year Award

Personalised medicine for childhood cancers in West Australia is a step closer thanks to the Zero Childhood Cancer program’s state clinical trial launched today